TX-FLUENCE
21.9.2022 15:11:14 CEST | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, has been selected by Wageningen University & Research (WUR) as the LED technology partner for its new Netherlands Plant Eco-phenotyping Centre (NPEC). In NPEC’s state-of-the-art phenotyping greenhouse, VYPR DUO 3x2 fixtures are used to support research on genotype-phenotype associations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220921005421/en/
In NPEC’s state-of-the-art phenotyping greenhouse, VYPR DUO 3x2 fixtures are used to support research on genotype-phenotype associations. (Photo: Business Wire)
The official opening of NPEC will take place preceding the weeklong International Plant Phenotyping Symposium 2022 (IPPS 2022), held from Sept. 26 to Sept. 30 in Wageningen, Netherlands. Fluence, a Gold Sponsor of IPPS 2022, will attend the conference and opening of NPEC in Wageningen.
NPEC consists of six modules across two university campuses, each offering dedicated phenotyping platforms with its own measurement systems. A specialized greenhouse at the WUR campus houses five climate-controlled compartments outfitted with Fluence’s VYPR DUO 3x2 fixtures. The compartments’ 3D and hyperspectral imaging, conveyor systems and various sensors produce high-precision measurements—including plant size, color and leaf positioning—that can be examined to understand the genetic response of plants to varied conditions and treatments, such as heat, drought or increased soil salinification.
“Using highly customizable technologies that generate high-quality plant performance data on how environmental parameters affect the plant phenotype was a key requirement when selecting our equipment partners,” said Rick van de Zedde, senior scientist and project manager for NPEC. “Having worked with Fluence for the lighting in our Serre Red high-tech quarantine greenhouse, we knew PhysioSpec™️ BROAD R4 white spectrum fixtures could help establish a near-ideal research environment in the NPEC greenhouse.”
In addition to Fluence’s VYPR top lights, which feature PhysioSpec™️ BROAD R4 white spectrum, NPEC researchers will use the Maxi-MARVIN imaging cabinet to assist in research, a high-throughput 3D modeling system developed by WUR that can reconstruct a plant’s architecture within milliseconds. Other high-tech research tools at WUR include a dark and light adaptation chamber and imaging systems capability to analyze the photosynthetic efficiency of plants.
“Establishing research on genotype-phenotype associations, specifically how ecological and environmental variables impact the plant phenotype, is essential for the development of novel, climate-proof crops,” explained van de Zedde. “Automated phenotyping will also allow for a dramatic increase in the speed of plant breeding and time to market for novel crop varieties.”
“We are honored to partner with WUR to advance the future of high-quality food production and sustainability in cultivation,” said Theo Tekstra, Fluence’s technical director for Europe, the Middle East and Africa and team lead for the WUR project. “Our PhysioSpec™️ BROAD R4 white spectrum came closest to what the WUR scientific team defined as an ideal spectrum to do year-round research on a wide range of plant species.”
Fluence's continuing partnership with WUR also includes LED fixtures in a specialized greenhouse for insect research and phenotyping climate rooms at Wageningen. Read more about Fluence’s collaborations with WUR here.
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005421/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access23.4.2026 10:00:00 CEST | Press release
Corpay Private Markets publishes its fourth Lender Book Report, drawing on proprietary transaction data and live lender appetite tracking across 500+ lenders Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions. The data reveals a structural gap. Although the number of GP
Pantheon Expands Global Private Wealth Platform with Infrastructure Secondaries Fund Launch23.4.2026 10:00:00 CEST | Press release
Now with new international vehicle, Pantheon offers clients global evergreen access to full suite of private equity, private credit secondaries, and infrastructure secondaries Pantheon bolsters its globally recognized, specialist approach in infrastructure secondaries in the evergreen market with the launch of the Pantheon Global Infrastructure Secondaries Fund (“PGIS”) PGIS will tap the expertise of Pantheon’s $26.9 billion1 institutional infrastructure franchise Fund marks latest in Pantheon’s growing, $15 billion2 global evergreen platform, which now includes semi-liquid evergreen offerings across private equity, private credit secondaries and infrastructure secondaries in the US and internationally3 Pantheon, a leading global private markets investor, today announced the regulatory approval for the Pantheon Global Infrastructure Secondaries Fund (“PGIS”). Domiciled in Luxembourg, the evergreen fund represents a significant milestone in Pantheon’s private wealth strategy and the exp
KAYTUS Unveils MotusAI Enhancements with OpenClaw for Enterprise-Grade AI Agents23.4.2026 09:02:00 CEST | Press release
Providing a high-availability compute foundation for seamless AI agent deployment, greater resource efficiency, and enterprise-grade reliability. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, today launched new capabilities in its MotusAI AI DevOps platform to accelerate the deployment of enterprise-grade AI agents. By a streamlined three-step integration with the OpenClaw framework, MotusAI provides the compute infrastructure, resource orchestration, and operational support required to address deployment bottlenecks, and enable AI agents to scale from early-stage experimentation to dependable enterprise use. Key Challenge for Enterprise-Grade AI Agents: Guaranteed Reliability and Performance As the AI landscape transitions from chatbots to AI agents, enterprises are facing a fundamental constraint: the value of even the most advanced large language model (LLM) depends on the stability and performance of the underlying execution infrastructure. At presen
Samsung Epis Holdings Reports First Quarter 2026 Financial Results23.4.2026 08:54:00 CEST | Press release
Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.” First Quarter 2026 Results On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KR
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency23.4.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the year delivering net sales of 1,473 million USD, predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy. Widespread net sales growth of 25.5% year-on-year at constant currency1,aligned with strong growth performance across geographies and product categories, including Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%). Continued market outperformance, with broad-based growth momentum across the existing portfolio, complemented by differentiated launches and geographic expansion. Demonstrated scientific leadership with new clinical data presented at major congresses, including positive phase II results for nemoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
